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Single use devices: Ready to Process 
(Microbial? Chemical?) 
(Why ?) 
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DRIVERS FOR SU - I 
 Higher upstream titers (reducing volume) 
 
 
 Shorter turn around times 
 
 
 Reduce water & buffer consumptions 
 
 
 Reduce foot print 
 
 
 Reduce maintenance 
 
 
 Reduce CAPEX & OPEX (?) 
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Assure Sterility (fool proof) 
 
 
Facilitate technology transfer 
 
 
Faster facility completion 
 
 
Reduce hazardous cleaning solutions 
 
 
Regulatory encouragement (?) 
 
 
Reduce risk for cross contamination 
DRIVERS FOR SU - II 
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CONCOMITANT  TRENDS - I 
Higher upstream titers 
 
 
 
 
Continuous processes 
 
 
 
 
Integrated processes 
 
 
 
 
Need for production in emerging countries 
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Improved process robustness (PAT, QbD) 
 
 
 
 
Increase in Non-platform processes 
 
 
 
 
Increase in use of CDMO (diversity) 
 
 
 
 
Need for “fail-proof” processes (autologous CT) 
CONCOMITANT  TRENDS - II 
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DISADVANTAGES (Perceptions…) - I 
Often single source supply 
 
 
 
No interoperability  (“protect” suppliers control) 
 
 
 
Non “inert” contact materials 
(Extractables|leachables|particulates|adsorption) 
 
 
 
Full product validation/testing difficult (BPSA) 
 
 
 
Still costly – non “disposable” SU? (eg. membranes)  
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DISADVANTAGES (Perceptions…) - II 
Sensors – disposable/reusable… 
 
 
Low nº of ports 
 
 
Limited to 2KL scale (? Sets options…) 
 
 
Material changes/logistics in “plastics” suppliers 
 
 
Aeration/agitation  (Ex., microbial ferment.) 
 
 
9 www.ibet.pt 
10 www.ibet.pt 
11 www.ibet.pt 
12 www.ibet.pt 
- SINGLE USE BIOREACTORS 
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Glass Stirred Tank Reactor (STR) versus disposable Mobius® CellReady (CR) 
STR Conditions: 
Sf9 cells (Life technologies) 
SF900II medium (Life technologies) 
27º C, pO2 = 30% 
Agitation = 70-250 rpm 
Aeration rate: 0.01 vvm 
Working volume = 2 L 
CCI = 1 x 106 cells/ml;  
MOI 2 for each baculovirus 
CR Conditions: 
Sf9 cells (Life technologies) 
SF900II medium (Life technologies) 
27º C, pO2 = 30% 
Agitation = 150 rpm 
Aeration rate: 0.01 vvm 
Working volume = 2 L 
CCI = 1 x 106 cells/ml;  
MOI 2 for each baculovirus 
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• Sf9 cells have similar growth profile in the two types of bioreactors 
Production of RetroVLP-HCV in bioreactor using Sf9 cells 
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Glass Stirred Tank Reactor (STR) versus disposable Mobius® CellReady (CR) 
GAG-MLV
CR
STR
HCV-E1
CR
STR
HCV-E2
CR
STR
VLP-HCV production kinetics in the bioreactors  
Final pure sample 
Gag-MLV titer (P30) in the bioreactors harvested bulk  
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Baculovirus replication kinetics in the bioreactors 
• Similar production kinetics for VLP-HCV in the two bioreactors 
• Similar final Gag productivity and baculovirus replication kinectis 
Production of RetroVLP-HCV in bioreactor using Sf9 cells 
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Mobius® CellReady 3L versus Mobius® CellReady 50L 
Mobius® 3L Conditions: 
Sf9 cells (Life technologies) 
SF900II medium (Life technologies) 
27º C, pO2 = 30% 
Agitation = 150 rpm 
Aeration rate: 0.01 vvm 
Working volume = 2 L 
CCI = 1 x 106 cells/ml;  
MOI 2 for each baculovirus 
Mobius® 50L Conditions: 
Sf9 cells (Life technologies) 
SF900II medium (Life technologies) 
27º C, pO2 = 30% 
Agitation = 110 rpm 
Aeration rate: 0.01 vvm 
Working volume = 50 L 
CCI = 1 x 106 cells/ml;  
MOI 2 for each baculovirus 
• Sf9 cells have similar growth profile in the Mobius® 3L and Mobius® 50L Bioreactors 
Infected Sf9 cells in M3L 
Infected Sf9 cells in M50L 
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  Scale-up of RetroVLP-HCV production: 2 L to 50 L 
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Mobius® CellReady 3L versus Mobius® CellReady 50L 
VLP-HCV production kinetics in the bioreactors  Gag-MLV titer (P30) in the bioreactors harvested bulk  
• Similar production kinetics for VLP-HCV in the Mobius® 3L and Mobius® 50L Bioreactors 
 
• Similar final Gag productivity 
0
20
40
60
80
100
Mobius® 50L Mobius® 3L Glass-STR 3L
G
ag
-M
LV
 C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
 
GAG-MLV 
Mobius 3L 
HCV-E1 
HCV-E2 
Mobius 3L 
Mobius 3L 
Mobius 50L 
Mobius 50L 
Mobius 50L 
Final pure sample 
Scale-up of RetroVLP-HCV production: 2 L to 50 L 
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Coping with the complexity of baculoviruses (rBVs) 
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• Measuring adsorption/electrostatics of the components of the bulk 
• Predicting the behavior of both the product of interest and the main 
impurities 
• Surface plasmon resonance (SPR) and dynamic light scattering 
(DLS) as potential tools 
Baculovirus bulk divided into three cuts: 
– Product: 
• Baculovirus, intact, purified, infective 
– Product-derived impurities: 
• Baculovirus, naked envelope 
• Baculovirus capsid 
• gp64 protein isolated 
• Baculovirus, empty-capsids 
– Process-derived impurities: 
• Host cell protein: BSA as model 
• DNA: cell nuclei DNA 
• Endotoxin: Lipopolysaccharide  
Ion-exchange chromatography: an interaction-driven 
process 
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SPR (I): a scaled-down tool 
• SPR used as a tool to obtain real-
time adsorption kinetics onto a 
customized DEAE anion-exchange 
sensor chip surface 
• Opportunities: 
>1200-fold scale-down; 
adsorption isotherms at varied salt 
concentration 
product and impurities 
model needed to express the 
readout into adsorption isotherms 
 
 
 
Vicente et al. 2010, Journal of Chromatography A, 
1217:2032-41. 
 
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   Scaling down 
Baculovirus 
Surface Plasmon Resonance (SPR) 
• Obtain real-time adsorption kinetics 
• Measurement of adsorption isotherms at various load 
conditions 
• Modeling IEX chromatography 
 
 
dP qi 
Vicente et al. 2010, Journal of Chromatography A, 1217:2032-41;   
Vicente et al. 2010, Journal of Biotechnology,148:171-181 
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• Proof of concept: predicting adsorption isotherms for a model 
complex biological system: rBVs and impurities 
Vicente et al. 2010, Journal of 
Biotechnology,148:171-181 
SPR (III): deconvoluting SPR data into adsorption isotherms 
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Vicente et al. 2010, Journal of Biotechnology,148:171-181 
• Prediction of binding capacity for product and impurities at broad 
salt concentration range 
SPR (IV): comparing product and major impurities 
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• Evaluation of the ζ-potential as a function of pH of the buffer 
• Estimation of hydrodynamic size distributions of rBVs (in buffer conditions) 
• Opportunities: 
prediction of interaction energies at 
varied salt concentration and pH; 
the above for the various components 
of the system: product and impurities 
not spherical-like 
charge density is not homogenous 
(gp64 localized in the baculovirus 
“head”) 
 
 
 
 
Vicente et al. 2010, Journal of Chromatography A, 
1217:3754-3764 
DLS (I): …yet another scaled-down tool 
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Scaling down 
Baculovirus 
Dynamic light scattering (DLS) 
• Evaluation of the ζ-potential as a function of pH of the 
buffer 
• Estimation of hydrodynamic size distributions of rBVs (in 
buffer conditions) 
• Prediction of electro kinetic properties of the different BV 
component 
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Vicente et al. 2010, Journal of Chromatography A, 
1217:3754-3764 
• Prediction of the interaction energies due 
to electric double layer at different 
conditions 
• 6 < pH < 10 
• rBV stability does matter! 
Uinteraction 
DLS (III): from ζ-potential data to a predictive model 
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• Decreasing ligand density 
does not affect virus binding 
as much as protein 
• The large size of the viruses 
prevents them to access all 
ligand sites 
Vicente et al. 2011, Biotechnology and Bioengineering, 108:6 1347-1359 
Improving purification performance: assessing ligand density 
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• 65% to 85% recovery yield 
improvement 
• Lower TP/IP, HCP, dsDNA 
SPR strategy set exploratory 
adsorption studies  
DLS strategy set operating 
conditions,  pH 7.2, I = 30 – 60 
mM NaCl 
 
Improving purification performance: assessing membrane prototypes 
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HTP, DoE, … 
Product recovery yield 
 85% 
a synergistic strategy 
Rational opt., DoE, … 
OK!  
time×costs 
time 
costs 
65% 
Rational design and optimization: 
a toolbox guiding process development 
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BIOPROCESSING OF HUMAN STEM CELLS  FOR CLINICAL APPLICATION @ IBET  
collaboration  
collaboration  
collaboration  
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STIRRED TANK BIOREACTOR 
100 μm 
30 
SCANNING ELECTRON MICROSCOPY & CONFOCAL MICROSCOPY (DAY 9 – BEFORE PURIFICATION) 
WAVE BIOREACTOR 
WAVE-INDUCED AGITATION ACCELERATES DIFFERENTIATION OF iPS 
CELLS INTO CMS 
HIGHER DEPOSITION OF COLLAGEN TYPE I 
DAPI/ αMHC-GFP / Collagen type I 
IMPACT OF THE AGITATION TYPE: STIRRED TANK VS. WAVE BR 
Correia et al 2014, Stem Cell Rev Rep 
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PRODUCTION OF iPSC-CMS: RESULTS 
No. of CMs  
No. of iPS cells   
Cardiomyocyte 
Differentiation Yield  
= 
The use of environmentally controlled bioreactors is critical to 
ensure Efficient and Scalable production of iPSC-derived CMs 
2.3 x109 CMs  
per 1L Wave bioreactor 
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Production of hMSCs (different sources: bone marrow, adipose tissue, umbilical cord tissue)
(for Autologous and Allogeneic Therapies)
AIM: Increase cell  volumetric productivities 
(cell/mL) without compromising cell quality 
(viability, identity and potency) 
UPSTREAM BIOPROCESSING  
Bioprocess Development: 
- Microcarrier type and concentration 
- Culture operation mode (fed-batch, perfusion) 
- Environmental conditions (e.g. pO2) 
-Establishment of cGMP compatible  processes 
- Process scale-up (from 100mL to 2L) 
- USP OF hMSC: CELL EXPANSION 
Cunha B et al 2015, Journal of Biotechnology  
Sousa et al 2015, Biotechnology Progress 
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Develop and prove scalability of an integrated and streamlined (and cGMP-
compatible) bioprocess comprising cell expansion, harvesting, clarification 
and volume reduction operations for hMSCs (hMSC-BM and hMSC-AT) 
vs 
Volume Reduction 
• Tangential flow filtration 
Hollow fiber 
cartridges 
Flat sheet 
cassettes 
Cell Harvesting & 
Clarification 
• Cell detachment 
• Microcarrier removal 
(dead end filtration) 
•  Microcarrier technology 
• xeno- and serum-free 
medium 
• Single-use bioreactors 
• Single use perfusion 
system 
 
 
Cell Expansion  
Evaluate the impact of critical process parameters on cell’s viability, recovery and purity 
SINGLE USE AND CELL THERAPY 
Establish a proteomics workflow based on Mass Spectrometry tools to characterize the 
impact of processing on cells’ CQA 
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hMSC-BM:  similar cell recoveries were achieved after 
scale-up (cell viability > 90%) 
hMSC-AT:  lower cell recovery after scale-up 
Scale-up criteria: P/V (power transferred by 
the impeller per volume, W/m3) constant 
100 µm 
Viable cells / Dead cells 
CELL HARVESTING: (1) SCALE-UP CELL DETACHMENT STEP IN BIOREACTORS 
Cell detachment from microcarriers in bioreactors : short periods of intense agitation in 
the presence of a detaching reagent    Protocol adapted from Nienow et al 2014 
Scale-up from 100mL to 1L 
Cunha B et al, Journal of Biotechnology,213:97-108, 2015 
35 www.ibet.pt 
Evaluation of scalable strategies for microcarrier removal 
 
Scaling-up: from 0.2 to 2 L 
OptiCap® XL 1 Capsules (EMD Millipore) 
(polypropylene, 100 µm pore size) 
Process 
Scale  
Cell Recovery 
(%) 
Cell Viability 
(%) 
BM-MSC 
0.2 L > 90% > 95% 
2 L 
94% 98% 
AT-MSC 95% 98% 
Cunha B et al 2015, Journal of Membrane Science, 478:117-129  |   Cunha B et al (2013) BMC Proceedings, 7 (Suppl 6) 
 Cell recovery yields and viability were maintained after scale-up 
CELL CLARIFICATION: (3) SCALE-UP 
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Process scale-up (up to 2 L): impact of TFF 
device ( Hollow Fibers vs Flat Sheet Cassettes) 
Impact of critical process parameters (CPP) (ex: membrane 
material, pore size, shear rate, permeate flux) on cells’ CQA 
and recovery yield 
Volume Reduction 
• Tangential flow filtration 
Hollow fiber 
cartridges 
Flat sheet 
cassettes 
vs 
  Aims 
VOLUME REDUCTION: AIMS 
1 
2 
Process validation with 2 hMSC 
(hMSC-BM and hMSC-AT) 3 
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Cunha B et al 2015, Journal of Membrane Science, 478:,  
￭ Membrane’s material  
 Polysulfone  
￭ Pore size 
 > 0.45 µm 
￭ Initial cell concentration 
 > 2 x 105 cell/mL 
￭ Shear rate 
 3000 s-1 
￭ Permeate flux 
 250 LMH 
￭ Operation mode 
 Discontinuous TFF 
VOLUME REDUCTION: (1) IMPACT OF CRITICAL PROCESS PARAMETERS 
In Cunha et al (2015) Journal of Membrane Science:   
 
 
 
 
 
Applicability of TFF to concentrate hMSC and hPSC (up to a VRF of 20); 
 Impact of TFF’s parameters on cell recovery yield and characteristics;  
TFF device: Hollow fibers 
WITH THE OPTIMIZED CONDITIONS:  
Cunha B et al, Journal of Membrane Science, 478:117-129, 2015 
38 www.ibet.pt 
PROCESS INTEGRATION 
Cunha B et al 2015, Journal of Biotechnology, 213:97-108; Cunha B et al 2017, Journal of Biotechnology, in press 
 
 
Integration: 
Closed system, resulting in the elimination of hold steps and decreasing the equip. footprint  
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PROCESS INTEGRATION- CELL CHARACTERIZATION 
Cunha B et al 2015, Journal of Biotechnology, 213:97-108; Cunha B et al 2017, Journal of Biotechnology, in press 
 
 
Cells maintain their quality attributes after DSP 
 hMSC maintained their immunophenotype and 
metabolic activity after processing; 
 Ability to adhere to plastic surfaces and 
proliferative capacity after re-plating 
Apoptosis, adhesion, viability 
40 www.ibet.pt Cunha B et al 2015, Journal of Biotechnology, 213:97-108 
Morphology and adhesion: hMSC successfully re-acquire their typical spindle-like morphology with 
organized actin fibers 
 
hMSC maintained their multilineage differentiation potential 
PROCESS INTEGRATION- CELL CHARACTERIZATION 
Cells maintain their critical quality attributes after DSP 
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Fluorescence-based bioprocess monitoring 
Fluorescence Excitation-Emission Matrix  
       Metabolites with intrinsic fluorescence 
Amino acids: Tryptophan, Tyrosine, Phenylalanine 
Cofactors: NADH, NADPH, FAD  
Vitamins: pyridoxine, thiamine, riboflavin, folic acid  
Advantages 
  Multi-component analysis 
  Different orders of magnitude 
  Non-destructive and non-invasive 
  Remote monitoring 
or Fluorescence Map 
Multivariate Data Analysis 
0
50
100
150
200
250
300
350
400
0
2
4
6
8
10
0 25 50 75 100 125 150 175
A
n
ti
b
o
d
y 
(m
g
/L
)
V
ia
b
le
 c
el
ls
 (
10
6 /
m
l)
time (h)
Target variables Y 
Input signal X 
PLS 
Teixeira et al. (2011) Biotech Bioeng 108: 1852-1861 
Teixeira et al. (2011) J Biotech 151:255-260 
Data collection over time 
Online fluorescence data 
Off-line measurements of target variables 
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Fluorescence maps over time 
Riboflavin/FAD NAD(P)H Tryptophan Pyridoxine 
Clone 1 
Clone 2 
Clone 3 
1h (after inoculation) 100h (end of exponential phase) 180h (end of culture) 
mAb-producing CHO cell cultures 
Teixeira et al. (2011) Biotech Bioeng 108: 1852-1861 
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Fluorescence-based predictors 
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IgG4 
Validation error = 6.6 % 
Good agreement  between 
model & offline measurements 
2D fluorometry  suitable for 
real-time monitoring of cell and 
mAb concentration  
Teixeira et al. (2011) Biotech Bioeng 108: 1852-1861 
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